Partnering

Apogenix wishes to establish a strategic partnership with a fully-committed partner for the late-stage clinical development and commercialization of its lead product, APG101, on a worldwide basis.
APG101 has been proven safe and excellently tolerated in preclinical and clinical trials. The substance is produced in a high-yield production process which allows for the production of, e.g., phase III material. The company has built a comprehensive patent portfolio protecting APG101 until 2024 and beyond. With its most advanced drug candidate, Apogenix is targeting commercially attractive indications with high unmet medical needs. APG101 is currently being developed for the treatment of glioblastoma and myelodysplastic syndrome.
In December 2009, a clinical phase II trial for the treatment of glioblastoma multiforme (GBM) was initiated. Enrolment was completed in September 2011 and final results will be available in Q1/2012.
Non-confidential information as well as preclinical and clinical data are available upon request.